Leptospirosis y coinfecciones durante el Niño Costero en un hospital del norte peruano

Herrera-Pérez, Dennis; Saavedra-Barón, Alexandra; Fernández-Mogollón, Jorge.
Rev. peru. med. exp. salud publica; 36(1): 148-150, ene.-mar. 2019. tab
Artigo em Espanhol | LILACS | ID: biblio-1004403

Documentos relacionados

  1. Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.
  2. Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion.
  3. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.
  4. A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study.
  5. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
  6. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study).
  7. RETINAL VEIN OCCLUSIONS BEFORE AND DURING THE COVID-19 PANDEMIC: Visual Outcomes and Treatment Patterns in a Country with no Mandatory Lockdown.
  8. Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
  9. Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab.
  10. Choroidal volume in branch retinal vein occlusion before and after intravitreal anti-VEGF injection.